Setmelanotide (BIM-22493; RM-493; IRC-022493; Imcivree) is a novel, selective and peptidyl agonist of melanocortin 4 receptor (MC4R) that has been approved in 2020 for use as an anti-obesity medication for the treatment of genetic obesity. It activates melanocortin 4 receptor (MC4R) with EC50s of 0.27 nM and 0.28 nM for human and rat MC4R, respectively.

纯度：≥98%

CAS：920014-72-8